Posted by Michael Wonder on 21 Apr 2022
Hansa Biopharma granted added benefit ASMR 3 by French Transparency Commission for Idefirix (imlifidase) as desensitisation treatment for highly sensitised kidney transplant patients
20 April 2022 - The opinion by the Transparency Commission follows after Idefirix was granted a funded Early Access Program by the French Haute Autorité de Santé in February this year.
Hansa Biopharma today announces that its treatment Idefirix has been granted an ASMR 3 rating by the Transparency Commission of the French National Authority for Health (HAS) as part of the on-going pricing and reimbursement process.
